Triaziquone

Triaziquone
Clinical data
Other names	2,3,5-Tris(aziridin-1-yl)cyclohexa-2,5-diene-1,4-dione; Tris(aziridinyl)-p-benzoquinone;
ATC code	L01AC02 (WHO) ;
Identifiers
	IUPAC name 2,3,5-tris(aziridin-1-yl)benzo-1,4-quinone;
CAS Number	68-76-8 ;
PubChem CID	6235;
ChemSpider	5999 ;
UNII	F3D5D9P25I;
KEGG	C19542 ;
ChEBI	CHEBI:27090 ;
CompTox Dashboard (EPA)	DTXSID1021370 ;
ECHA InfoCard	100.000.629
Chemical and physical data
Formula	C12H13N3O2
Molar mass	231.255 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN1C2=CC(=O)C(=C(C2=O)N3CC3)N4CC4;
	InChI InChI=1S/C12H13N3O2/c16-9-7-8(13-1-2-13)12(17)11(15-5-6-15)10(9)14-3-4-14/h7H,1-6H2 ; Key:PXSOHRWMIRDKMP-UHFFFAOYSA-N ;
	(what is this?) (verify)

Triaziquone is a drug used in chemotherapy.

It is aziridinylbenzoquinone-based, and may have potential antineoplastic activity. ^[1]

It is an alkylating agent. It can react with DNA to form intrastrand crosslinks. It is a member of aziridines as well. ^[2]

References

^ PubChem. "Triaziquone". pubchem.ncbi.nlm.nih.gov. Retrieved 2023-10-10.
^ Huang CH, Kuo HS, Liu JW, Lin YL (June 2009). "Synthesis and antitumor evaluation of novel bis-triaziquone derivatives". Molecules (Basel, Switzerland). 14 (7): 2306–16. doi:10.3390/molecules14072306. PMC 6255275. PMID 19633605.